Optomed’s board has resolved upon a new option plan

Report this content

Optomed Plc         Stock Exchange Release    22 October 2020 at 9.00, Helsinki

Optomed’s board has resolved upon a new option plan

Optomed’s board of directors has resolved upon a new option plan. The resolution is based on the authorization given by the general meeting of 11 June 2020.

Option plan 2020A:

The total maximum number of options is 150,000 and each option entitled to one share of the company. The options are offered to certain key employees. The purpose of the plan and the basis for the subscription price is the payment of certain incentives that were previously agreed in connection with the acquisition of Optomed Software Oy and to retain key employees. The subscription price is EUR 3.50 and the subscription period is 1 January 2023 – 31 December 2023.

The theoretical market value of one option under the plan 2020A is approximately EUR 2.97 per stock option and the theoretical total market value of the plan 2020A is approximately 445,500 euros in total. The theoretical market value of a stock option has been calculated by using the closing price of 19th October 2020 and the Black & Scholes stock option pricing model with the following input factors: share price EUR 5.55 euros, subscription price EUR 3.50, risk free interest rate -0.75%, validity of stock options approximately 3.2 years and volatility 59.51%.

The complete terms and conditions of the option plan 2020A are attached to this release.

Optomed Plc

Further enquiries

Petri Salonen, Chairman of the Board, Optomed Plc, petri.salonen@optomed.com

Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com

Optomed in Brief 

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 55 international patents protecting the technology. In 2019, Optomed’s revenue reached EUR 15 million and 2018 pro forma revenue amounted to EUR 14.5 million. At the end of 2019, Optomed employed 108 professionals.


Documents & Links